Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332]

  • In development
  • GID-TA11233
  • Expected publication date: 

NIHRIO BN: Microsoft Word - 29564 (TSID_10556) Enfortumab vedotin+Pembrolizumab for UC V1.0 NOV22 NON CONF (nihr.ac.uk)